Products for Research Use Only
RegisterLogin

Setipiprant

CAT: 0804-HY-16635-01Size: 25 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-16635-01Size:25 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Setipiprant (ACT-129968) is an orally active and selective CRTH2 antagonist. Setipiprant interacts with hCRTH2 receptor with an IC50 value of 6 nM. Setipiprant inhibits prostanoid receptors hDP1 and hEP2 with IC50 values of 1290 and 2600 nM, respectively. Setipiprant can be used for the research of asthma and rhinitis[1].
CAS Number
866460-33-5
Product Name Alternative
ACT-129968; KYTH-105
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
CRTH2 (GPR44) ; Prostaglandin Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Endocrinology
Assay Protocol
https://www.medchemexpress.com/Setipiprant.html
Purity
98.23
Solubility
DMSO : ≥ 36 mg/mL
Smiles
O=C(O)CN1C2=C(CN(C(C3=C4C=CC=CC4=CC=C3)=O)CC2)C5=C1C=CC(F)=C5
Molecular Formula
C24H19FN2O3
Molecular Weight
402.42
Precautions
H302, H315, H319, H335
References & Citations
[1]Heinz Fretz, et al. Identification of 2 (2- (1-Naphthoyl) -8-fluoro-3,4-dihydro 1H pyrido[4,3 b]indol-5 (2H) yl) acetic Acid (Setipiprant/ACT 129968), a Potent, Selective, and Orally Bioavailable Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) Antagonis. 2013.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
DP; EP

Alternative Products

CatalogName
RG-A260949-01Setipiprant
C11316-25mgSetipiprant (ACT-129968)
MBS3841185-01ACT-129968 (Setipiprant)
A15780-200ACT-129968 (Setipiprant) 200mg
A15780-100ACT-129968 (Setipiprant) 100mg
A15780-50ACT-129968 (Setipiprant) 50mg
A15780-10mM-DACT-129968 (Setipiprant) 10mM * 1mL in DMSO

Popular Products